Mockup Marketing Assets - Signatera Breast Cancer
A New Standard in Personalized Breast Cancer Surveillance - Signatera™
Detection of Molecular Residual Disease (MRD) Enables Earlier Detection and Targeted Intervention
02
LinkedIn post
🚀 Advancing Precision Oncology: Early Detection with Signatera
In oncology, detecting disease early—before it’s visible via imaging—can change everything.
The Signatera™ assay by Natera is a personalized, tumor-informed ctDNA test that identifies molecular residual disease (MRD) to detect recurrence earlier and guide clinical decisions with greater confidence.
Why it matters:
🔹 Enables earlier intervention and more informed treatment planning
🔹 Translates complex genomic insights into actionable patient care
🔹 Supports precision oncology through truly personalized monitoring
👉 Learn more about the science and evidence behind Signatera here:
#Oncology #ctDNA #MRD #PrecisionMedicine #GeneticTesting
03
Instagram Post
This is your Project description. Provide a brief summary to help visitors understand the context and background of your work. Click on "Edit Text" or double click on the text box to start.
04
This is your Project description. Provide a brief summary to help visitors understand the context and background of your work. Click on "Edit Text" or double click on the text box to start.
